Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9132735 | 0.79 | — | — | |
| SCHEMBL9769231 | 0.77 | — | — | |
| SCHEMBL49872 | 0.75 | ALDH1A1 (0.32) | — | |
| SCHEMBL1503381 | 0.75 | ALDH1A1 (0.30) | — | |
| SCHEMBL9214276 | 0.73 | — | — | |
| SCHEMBL28089252 | 0.73 | ALDH1A1 (0.31) | — | |
| SCHEMBL19405600 | 0.73 | TAAR1 (0.30) | — | |
| SCHEMBL28470907 | 0.73 | ALDH1A1 (0.31) | — | |
| SCHEMBL7074177 | 0.72 | — | — | |
| SCHEMBL10631014 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115819668-A | Aggregation-induced emission-based temperature-sensitive polymer and preparation method and application thereof | 宁波大学 | 2023-03-21 | — | — | CN | claimed |
| CN-115819668-A | Aggregation-induced emission-based temperature-sensitive polymer and preparation method and application thereof | 宁波大学 | 2023-03-21 | — | — | CN | disclosed |
| EP-3303337-B1 | FUSED TRICYCLIC IMIDAZO PYRAZINES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-05-27 | — | — | EP | disclosed |
| US-10472362-B2 | Fused tricyclic imidazo pyrazines as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2019-11-12 | — | — | US | disclosed |
| EP-3080114-B1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-10-02 | — | — | EP | disclosed |
| US-20180298006-A1 | Fused Tricyclic Imidazo Pyrazines as Modulators of TNF Activity | UCB S.A. (BE) | 2018-10-18 | — | — | US | disclosed |
| EP-3303337-A1 | FUSED TRICYCLIC IMIDAZO PYRAZINES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2018-04-11 | — | — | EP | disclosed |
| US-9890174-B2 | Fused Tricyclic imidazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-02-13 | — | — | US | disclosed |
| WO-2016198398-A1 | FUSED TRICYCLIC IMIDAZO PYRAZINES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2016-12-15 | — | — | WO | disclosed |
| US-20160304530-A1 | Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity | UCB PHARMA S.A. (BE) | 2016-10-20 | — | — | US | disclosed |
| US-20060014737-A1 | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| WO-2005087714-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087215-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087752-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005070407-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | DNPEP, ASPH, PEPD | HDAC8 273/4885 |
| US-20180298006-A1 | Fused Tricyclic Imidazo Pyrazines as Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | HDAC8 759/4885 |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | HDAC8 2171/4885 |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | APP, DNPEP, BACE1 | HDAC8 3103/4885 |
| US-20060014737-A1 | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors | DNPEP, ASPH, APP | HDAC8 2537/4885 |
| US-10472362-B2 | Fused tricyclic imidazo pyrazines as modulators of TNF activity | TNF, TNFRSF1A, TNFRSF9 | HDAC8 853/4885 |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | HDAC8 2171/4885 |
| US-20160304530-A1 | Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | HDAC8 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.